[Current possibilities in the therapy of iron overload]
Related Experiment Videos
1Ustav hematologie a krevní transfuze, Praha.
Insights
Chronic iron overload causes organ damage. Oral iron chelators like Deferiprone show promise but have serious side effects, necessitating research into safer alternatives for treating iron overload.
Area of Science:
- * Pharmacology
- * Medicinal Chemistry
- * Clinical Medicine
Context:
- * Chronic iron accumulation leads to significant tissue damage, cardiac, and hepatic failure.
- * Current standard treatment, desferrioxamine (Desferal), requires parenteral administration.
- * Need for orally active iron chelators with efficacy comparable to desferrioxamine.
Purpose:
- * To review the development and challenges of orally active iron chelators.
- * To highlight hydroxypyridones, particularly 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone), as promising candidates.
- * To discuss ongoing research into alternative oral iron chelators.
Summary:
- * Desferrioxamine is the only approved chelator, but requires infusion.
- * Oral hydroxypyridones, like Deferiprone, demonstrate effective iron excretion.
- * Deferiprone's clinical use is limited by adverse effects such as agranulocytosis.
- * Other oral chelators like PIH and HBED are under investigation.
Impact:
- * Development of safe, inexpensive, orally effective iron chelators is crucial.
- * Improved treatment options for iron overload patients.
- * Potential to prevent organ damage and improve cardiac and liver function.
Abstract:
Tissue damage, cardiac and hepatic failure are the most frequent consequences of chronic iron accumulation within the body. A long term administration of chelating agents may prevent organ damage by surplus of iron as well as improve cardiac and liver function in iron overloaded patients. Desferrioxamine (Desferal) is the only one chelating agent for routine clinical use. To produce a therapeutic effect parenteral administration of the drug in prolonged infusions is needed and therefore many investigators try to search for orally active chelator with effect comparable to desferrioxamine. Hydroxypyridones, especially 1,2-dimethyl-3-hydroxypyrid-4-one (L 1-Deferiprone), are the most intensively studied oral iron chelators. In animal and clinical studies L 1 administration caused iron excretion comparable to that obtained by desferrioxamine, however, some serious adverse effects (including agranulocytosis) related to L 1 treatment were observed. This problem still precludes wide large-scale clinical application of L 1. Other compounds possessing chelating activity after oral administration, eg. 1,2-diethyl-3-hydroxypyridone, PIH or HBED are also currently under investigation. Development of a safe inexpensive and orally effective iron chelator is the main objective of ongoing animal and clinical studies.